AI-Based Remote Test for Parkinson’s Disease Severity Shows Promise

By Michael Awood

September 17, 2023

People with Parkinson’s disease rarely receive proper care because of a lack of access to neurological care. In the US, about 40% of those aged 65 or older with PD do not receive care from a neurologist. Access is even more limited in developing regions. Experts suggest an AI-based method to measure Parkinson’s disease severity using a remote finger-tapping test.

Researchers developed a model that uses AI techniques to evaluate motor performance severity of patients. Through performing finger-tapping tasks at home, they analysed the patients with a webcam. A panel of experts and non-experts validated its features, which correlated strongly with the experts’ ratings.

This research shows that remote assessment of the finger-tapping task can be done with reliability. AI models have the potential to perform as well as clinicians and outperform non-specialists in assessing the task, according to the study. The model had an equal performance for all subgroups, suggesting its potential wide adoption in movement disorders.

The tool could enable longitudinal tracking of symptom progression, helping to fine-tune PD treatment. Clinical visits can use it to track PD progression and augment neurologists’ ability to analyze videos with digital biomarkers. In areas with a scarcity of neurologists, the tool could assess symptoms frequently and refer the patient to a neurologist if necessary.

However, the model was not without its limitations. Sometimes, it misclassified severity scores and showed poor accuracy. The model worked well in both high and low-quality videos, making it difficult to evaluate videos taken outside clinical settings. Researchers emphasised ethical considerations as data security, user privacy, and algorithmic bias. When introducing the tool in healthcare settings, these need reviewing.

The researchers also suggest future improvements. These included addressing the impact of tremors on finger-tapping, increasing the sample size, and balancing severity scores as a few improvements to the study.

 

Cover image taken from the research article

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.